LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mesa Receives FDA EUA for 30 Minute POC Molecular COVID-19 Test

By LabMedica International staff writers
Posted on 27 Mar 2020
Print article
Image: Mesa’s Accula SARS-CoV-2 Test (Photo courtesy of Mesa Biotech)
Image: Mesa’s Accula SARS-CoV-2 Test (Photo courtesy of Mesa Biotech)
Mesa Biotech (San Diego, CA, USA) has received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) for its Accula SARS-CoV-2 Test, which gives COVID-19 diagnostic results in 30 minutes. Mesa has also developed an affordable, easy to use testing platform designed for point-of-care (POC) infectious disease diagnosis. The COVID-19 test uses this patented technology to enable 'near patient' testing allowing testing outside of the central laboratory.

Mesa, a privately-held, molecular diagnostic company, designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid polymerase chain reaction (PCR) amplification to the POC. Last week, the company had received funding from the US Health and Human Services for the development of its SARS-CoV-2 test. Mesa’s Accula SARS-CoV-2 Test is a visually read test using PCR technology to detect SARS-CoV-2, the virus responsible for COVID-19, via throat and nasal swab samples. Similar to Mesa’s commercially available tests for influenza and RSV, the Accula SARS-CoV-2 Test is designed for the POC use, including temporary screening facilities, physician office labs, urgent care, and long-term nursing facilities.

"Mesa is excited to immediately begin shipping our rapid, molecular SARS-CoV-2 test so people can get answers in 30 minutes. Our Accula system is easy to use and fits in the palm of your hand. This allows many units to be run side by side in the doctor's office further increasing the speed of COVID-19 diagnosis. Accula provides a true decentralized testing solution for COVID-19 at the point of care," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. "Our test will provide a highly accessible means for healthcare professionals to access laboratory quality results close in their office to aid in the decision to isolate, treat or dismiss potential carriers of the virus. The potential to reduce the growing strain on our nation's hospitals is tremendous."

Related Links:
Mesa Biotech

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more